GHRP-6
Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Insulinotropic action of bombesin-like peptides mediated by gastrin-releasing peptide receptors in steers.
Zhao. H Q HQ; Yao. G G; Yannaing. S S; ThanThan. S S; Kuwayama. H H
Key Findings
- Injecting GRP or NMC into steers sharply increased insulin within 5 minutes.
- A GRP‑receptor antagonist stopped the insulin and glucose changes, while the GHRP‑6 antagonist did not.
- GHRP‑6 (a GHS‑R1a blocker) does not interfere with the insulinotropic effect of bombesin‑like peptides.
Practical Outcomes
- For self‑experimenters using GHRP‑6 to boost growth hormone, this study suggests it likely won’t affect insulin release via GRP receptors, but the research was done in cattle, so the findings may not translate directly to humans. No specific dosing or protocol changes can be drawn from this work.
Summary
In a study on cattle, two bombesin-like peptides (GRP and NMC) caused a quick rise in insulin, but this effect was blocked by a GRP‑receptor blocker and NOT by the GHRP‑6 compound that blocks the ghrelin receptor. This means the insulin‑boosting action works through GRP receptors, not the ghrelin/GHS‑R1a pathway that GHRP‑6 targets.
Abstract
The present study characterizes the receptor that mediates the insulinotropic action of bombesin-like peptides (BLP) in ruminants. Eight Holstein steers were randomly and intravenously injected with synthetic bovine gastrin-releasing peptide (GRP; 0.9 nmol/kg BW), neuromedin B (NMB; 0.9 nmol/kg BW), or neuromedin C (NMC; 0.9 nmol/kg BW), each alone or combined with the antagonist of GRP receptors N-acetyl-GRP-OCHCH (N-GRP-EE; 22.5 nmol/kg BW) or the antagonist of GH secretagogue receptor type 1a (GHS-R1a) [D-Lys]-GHRP-6 (21.5 nmol/kg BW). Blood samples were collected at -10, 0 (just before injection), 5, 10, 15, 20, 30, 45, 60, 75, and 90 min relative to injection time. Levels of injected peptides, insulin, and glucose in plasma were analyzed. Results showed that the peak of insulin levels was seen at 5 min after injection of NMC or GRP. Plasma glucose was observed in 2 phases; a significant rise followed a remarkable fall after NMC or GRP administration compared with injection of the vehicle ( < 0.05). On a same molar basis, effects of GRP on insulin and glucose were more potent than those of NMC ( < 0.05). The NMC-induced changes of insulin and glucose were completely blocked by N-GRP-EE, but [D-Lys]-GHRP-6 did not block any of these changes. Administration of NMB or N-GRP-EE alone did not change the circulating levels of insulin or glucose during any of the sampling time points ( > 0.05). These results indicated that the insulinotropic action of BLP is mediated by GRP receptors but not through a ghrelin/GHS-R1a pathway and that BLP may be involved in the regulation of glucose homeostasis in ruminants.
Study Information
pubmed
2016
10.2527/jas.2015-9495
1
27